Clinical Trial Update: Evaluation of Efficacy and Safety of BF-200 ALA Used With Photodynamic Therapy in Patients With Actinic Keratosis. [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating BF-200 ALA with photodynamic therapy in actinic keratosis has completed and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• BF-200 ALA (5-aminolevulinic acid (ALA) topical photosensitizer)

Snippet

Sponsor: Biofrontera Bioscience GmbH | Conditions: Actinic Keratosis | Phase 3 | Status: COMPLETED | Results posted: 2017-04-06